Skip to main content

Table 1 Assumptions for planned, preventive SIAs (pSIAs) through OPV2 cessation in OPV-using blocks that interrupted indigenous wild poliovirus transmission (adapted from Thompson and Duintjer Tebbens (2015) [26])

From: Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs

Time period RI coverage (POL3) SIA schedule showing: vaccine (day(s) of year)
Before tOPV intensification on January 1, 2015 0.05 or 0.1 tOPV (0, 40); bOPV (80, 140, 240, 300)
0.3 tOPV (0, 40); bOPV (80, 140, 240)
0.6 (R0 ≤ 10) tOPV (0); bOPV (60, 120)
0.6 (R0 > 10) tOPV (0, 40); bOPV (80, 140, 240)
0.9 tOPV (0)
0.98 (R0 ≤ 10) No SIAs
0.98 (R0 > 10) tOPV (0)
During tOPV intensification (January 1, 2015 to April 1, 2016) 0.05 or 0.1 tOPV (0, 40, 80, 300); bOPV (140, 240)
0.3 tOPV (0, 40, 80); bOPV (140, 240)
0.6 (R0 ≤ 10) tOPV (0, 60); bOPV (120)
0.6 (R0 > 10) tOPV (0, 40, 80); bOPV (140, 240)
0.9 tOPV (0)
0.98 (R0 ≤ 10) No SIAs
0.98 (R0 > 10) tOPV (0)
After tOPV intensification (April 1, 2016 to April 1, 2017 or later) 0.05 or 0.1 bOPV (0, 40, 80, 140, 240, 300)
0.3 bOPV (0, 40, 80, 140, 240)
0.6 (R0 ≤ 10) bOPV (0, 60, 120)
0.6 (R0 > 10) bOPV (0, 40, 80, 140, 240)
0.9 bOPV (0)
0.98 (R0 ≤ 10) No SIAs
0.98 (R0 > 10) bOPV (0)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us